Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides; Lucia Masarova; Mansour Alfayez; Naval Daver; Yesid Alvarado; Elias Jabbour; Marina Konopleva; Hagop M. Kantarjian; Keyur P. Patel; Courtney D. DiNardo; Srdan Verstovsek

doi:10.1182/BLOODADVANCES.2020001528

Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Original language	English (US)
Pages (from-to)	5336-5342
Number of pages	7
Journal	Blood Advances
Volume	4
Issue number	21
DOIs	https://doi.org/10.1182/BLOODADVANCES.2020001528
State	Published - Oct 28 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/BLOODADVANCES.2020001528

Cite this

@article{217f611578764beaadd34f5dec252be9,

title = "Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors",

author = "Chifotides, {Helen T.} and Lucia Masarova and Mansour Alfayez and Naval Daver and Yesid Alvarado and Elias Jabbour and Marina Konopleva and Kantarjian, {Hagop M.} and Patel, {Keyur P.} and DiNardo, {Courtney D.} and Srdan Verstovsek",

note = "Funding Information: Acknowledgments This research was supported, in part, by the MD Anderson Cancer Center Support Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health. C.D.D. is a recipient of the Lloyd Family/V Foundation Clinical Scholar Award.",

year = "2020",

month = oct,

day = "28",

doi = "10.1182/BLOODADVANCES.2020001528",

language = "English (US)",

volume = "4",

pages = "5336--5342",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

AU - Chifotides, Helen T.

AU - Masarova, Lucia

AU - Alfayez, Mansour

AU - Daver, Naval

AU - Alvarado, Yesid

AU - Jabbour, Elias

AU - Konopleva, Marina

AU - Kantarjian, Hagop M.

AU - Patel, Keyur P.

AU - DiNardo, Courtney D.

AU - Verstovsek, Srdan

N1 - Funding Information: Acknowledgments This research was supported, in part, by the MD Anderson Cancer Center Support Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health. C.D.D. is a recipient of the Lloyd Family/V Foundation Clinical Scholar Award.

PY - 2020/10/28

Y1 - 2020/10/28

UR - http://www.scopus.com/inward/record.url?scp=85096638892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096638892&partnerID=8YFLogxK

U2 - 10.1182/BLOODADVANCES.2020001528

DO - 10.1182/BLOODADVANCES.2020001528

M3 - Article

C2 - 33112940

AN - SCOPUS:85096638892

SN - 2473-9529

VL - 4

SP - 5336

EP - 5342

JO - Blood Advances

JF - Blood Advances

IS - 21

ER -

Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this